ReviewJournal of labelled compounds & radiopharmaceuticals2018
PET radiometals for antibody labeling.
Review in Journal of labelled compounds & radiopharmaceuticals, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 65 citations in OpenAlex.
- Enhanced Tumor-to-Background Contrast with [Pharmaceuticals (Basel, Switzerland) · 2026Article
- Development ofMolecular imaging and biology · 2024Article
- Peptide PET Imaging: A Review of Recent Developments and a Look at the Future of Radiometal-Labeled Peptides in Medicine.Chemical & biomedical imaging · 2024Review
- Zirconium 89 and Copper 64 for ImmunoPET: From Antibody Bioconjugation and Radiolabeling to Molecular Imaging.Pharmaceutics · 2024Review
- Production of the PET radionuclideEJNMMI radiopharmacy and chemistry · 2024Article
- Copper radionuclides for theranostic applications: towards standardisation of their nuclear data. A mini-review.Frontiers in chemistry · 2023Review
- Targeting Tumor-Associated Macrophages for Imaging.Pharmaceutics · 2022Review
- Multimodal imaging demonstrates enhanced tumor exposure of PEGylated FUD peptide in breast cancer.Journal of controlled release : official journal of the Controlled Release Society · 2022Article
- Pretargeted PET Imaging with a TCO-Conjugated Anti-CD44v6 Chimeric mAb U36 and [Bioconjugate chemistry · 2022Article
- Positron Emission Intensity in the Decay ofMolecules (Basel, Switzerland) · 2022Article
- Expanding the PET radioisotope universe utilizing solid targets on small medical cyclotrons.RSC advances · 2021Review
- State of the Art in Radiolabeling of Antibodies with Common and Uncommon Radiometals for Preclinical and Clinical Immuno-PET.Bioconjugate chemistry · 2021Article
- Radiochemistry, Production Processes, Labeling Methods, and ImmunoPET Imaging Pharmaceuticals of Iodine-124.Molecules (Basel, Switzerland) · 2021Review
- Automated, cassette-based isolation and formulation of high-purity [EJNMMI radiopharmacy and chemistry · 2020Article
- Synthesis of a novelEJNMMI research · 2020Article
- Methods to Enhance the Metabolic Stability of Peptide-Based PET Radiopharmaceuticals.Molecules (Basel, Switzerland) · 2020Review
- Coordination chemistry of [Y(pypa)]Dalton transactions (Cambridge, England : 2003) · 2020Article
- ImmunoPET: Concept, Design, and Applications.Chemical reviews · 2020Review
- Review
- Current outlook on radionuclide delivery systems: from design consideration to translation into clinics.Journal of nanobiotechnology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Recent advances in molecular characterization of tumors have made possible the emergence of new types of cancer therapies where traditional cytotoxic drugs and nonspecific chemotherapy can be complemented with targeted molecular therapies. One of the main revolutionary treatments is the use of monoclonal antibodies (mAbs) that selectively target the disseminated tumor cells while sparing normal tissues. mAbs and related therapeutics can be efficiently radiolabeled with a wide range of radionuclides to facilitate preclinical and clinical studies. Non-invasive molecular imaging techniques, such as Positron Emission Tomography (PET), using radiolabeled mAbs provide useful information on the whole-body distribution of the biomolecules, which may enable patient stratification, diagnosis, selection of targeted therapies, evaluation of treatment response, and prediction of dose limiting tissue and adverse effects. In addition, when mAbs are labeled with therapeutic radionuclides, the combination of immunological and radiobiological cytotoxicity may result in enhanced treatment efficacy. The pharmacokinetic profile of antibodies demands the use of long half-life isotopes for longitudinal scrutiny of mAb biodistribution and precludes the use of well-stablished short half-life isotopes. Herein, we review the most promising PET radiometals with chemical and physical characteristics that make the appealing for mAb labeling, highlighting those with theranostic radioisotopes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.